<DOC>
	<DOCNO>NCT02304198</DOCNO>
	<brief_summary>This study evaluate long-term safety Udenafil Patient Pulmonary Arterial Hypertension ( PAH ) . All patient receive Udenafil 1-year ( 48-weeks ) .</brief_summary>
	<brief_title>Clinical Trial Evaluate Long-term Safety Udenafil Patient With PAH</brief_title>
	<detailed_description>Pulmonary arterial Hypertension characterize progressive incerease pulmonary vascular resistance ( PVR ) lead right ventricualar failure . Udenafil inhibit PDE 5 , enzyme metabolizes cGMP , enhance cGMP mediate relaxation growth inhibition vascular smooth muscle cell , include lung .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>Patients complete initial study ( DA8159_PAH_II ) , 12week , doubleblind , placebocontrolled trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>